NDUFA13
ENSG00000186010
Target class
Enzyme
Chromosome
19
Approved drugs
1
Clinical candidates (approved and in development)
3
- Approved drugs
- 1
- ClinGen gene-disease validity
- Moderate
- Clinical candidates (approved and in development)
- 3
- Chemical probe available
- No
- Target name
- NDUFA13
- Gene name
- NADH:ubiquinone oxidoreductase subunit A13
- Gene symbol
- NDUFA13
- Protein name
- NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13 (Cell death regulatory protein GRIM-19) (Complex I-B16.6) (CI-B16.6) (Gene associated with retinoic and interferon-induced mortality 19 protein) (GRIM-19) (Gene associated with retinoic and IFN-induced mortality 19 protein) (NADH-ubiquinone oxidoreductase B16.6 subunit)
- CGI-39
- CDA016
- GRIM-19
- GRIM19
- B16.6
- Gene biotype
- Protein coding
- Gene family
- NADH:ubiquinone oxidoreductase supernumerary subunits
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 261.47
- Tissue specificity (Gini)
- 0.135
- Tissue specificity (tau)
- 0.552
- KEGG gene identifiers
- hsa:51079
- Protein interaction confidence
- 0.9206
- Protein interaction partners
- 125
- R-HSA-611105
- R-HSA-6799198
- R-HSA-9837999
- End position
- 19529054
- Start position
- 19515736
- Chromosome
- 19
- Strand
- Forward
- Mitochondrion inner membrane
- Single-pass membrane protein
- Matrix side. Nucleus . Note=Localizes mainly in the mitochondrion (PubMed:12628925). May be translocated into the nucleus upon IFN/RA treatment. .
- Mitochondria
- PubMed 12628925
- PubMed 15059901
- PubMed 15367666
- Tissue specificity (tau)
- 0.551985
- Expression inequality (Gini)
- 0.135435
Expression in transcripts per million
- Testis
- 261.47
- Heart - Left Ventricle
- 190.77
- Heart - Atrial Appendage
- 181.52
- Pituitary
- 162.44
- Brain - Frontal Cortex (BA9)
- 149.65
Expression in transcripts per million
- Testis261.47
- Heart - Left Ventricle190.77
- Heart - Atrial Appendage181.52
- Pituitary162.44
- Brain - Frontal Cortex (BA9)149.65
- Thyroid147.07
- Kidney - Medulla143.68
- Muscle - Skeletal139.24
- Brain - Nucleus accumbens (basal ganglia)138.89
- Artery - Aorta132.72
- Colon - Sigmoid132.27
- Cells - Cultured fibroblasts132.25
- Cervix - Ectocervix132.18
- Prostate131.56
- Brain - Anterior cingulate cortex (BA24)130.23
- Cells - EBV-transformed lymphocytes130.17
- Cervix - Endocervix128.8
- Fallopian Tube128.55
- Artery - Coronary126.18
- Brain - Putamen (basal ganglia)125.9
- Brain - Cerebellar Hemisphere125.58
- Brain - Caudate (basal ganglia)125.17
- Brain - Substantia nigra124.97
- Brain - Hypothalamus124.87
- Brain - Cerebellum124
And 29 more, listed on the interactive page.
- GO:0032981
- GO:0035458
- GO:0045039
- GO:0045732
- GO:0045892
- GO:0071300
- GO:1900119
- GO:0005634
- GO:0005654
- GO:0005737
- GO:0005739
- GO:0005743
- GO:0031966
- GO:0045271
- GO:0098803
- GO:0005515
- GO:0061133
Related records
Trials (2,107)
- "Hepatic Substrate Flux Rates in Type 2 Diabetes"
- "MetCool ACS"- Metformin "Cooling" Effect on Metformin-naive Patients Treated With PCI Because of Acute Coronary Syndrome
- 1% Metformin Gel in the Treatment of Class II Furcation Defects
- 1% Metformin in Moderate and Severe Periodontitis
- 12 Weeks Treatment With 3 Different Doses of BI 10773 in Type 2 Diabetic Patients
- 24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes
- 24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years
- 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine
- 30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)
- 52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period
- A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)
- A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 12.5 mg and MET XR 500 mg) in Healthy Volunteers
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 25 mg and MET XR 1,000 mg) in Healthy Volunteers
- A Bioequivalence Study Of Ethinylestradiol + Gestodene In Female And Healthy Volunteers.
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of the Fixed Dose Combinations of Saxagliptin/Metformin XR Relative to Co-Administration
Drugs (4)
- ME-344 Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Metformin Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Metformin hydrochloride Mitochondrial complex I (NADH dehydrogenase) inhibitor
- NV-128 Mitochondrial complex I (NADH dehydrogenase) inhibitor